SEC filer · CIK 0000862692 · CCEL
Cryo-Cell International, Inc.
Cryo-Cell International net income: -$2.43 million for the year ending 2025-11-30. Total assets: $61.7 million at 2025-11-30.
Every reported measure
The latest value of each measure the company reports, as filed. Choose one for its full history, its definition and the filing behind each figure. Separate currencies and reporting intervals stay separate rows; these are reported amounts, not prices.
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Total assets | - | 2025-11-30 | $61.7 million | 2026-02-27 |
| Total liabilities | - | 2025-11-30 | $80.3 million | 2026-02-27 |
| Stockholders equity | - | 2025-11-30 | -$18.6 million | 2026-02-27 |
| Cash and cash equivalents | - | 2025-11-30 | $319.0 thousand | 2026-02-27 |
| Net income or loss | 2024-12-01 | 2025-11-30 | -$2.43 million | 2026-02-27 |
| Operating cash flow | 2024-12-01 | 2025-11-30 | $5.48 million | 2026-02-27 |
| Capital expenditure payments | 2024-12-01 | 2025-11-30 | $230.5 thousand | 2026-02-27 |
| Financing cash flow | 2024-12-01 | 2025-11-30 | -$4.75 million | 2026-02-27 |
| Investing cash flow | 2024-12-01 | 2025-11-30 | -$975.3 thousand | 2026-02-27 |
| Retained earnings or deficit | - | 2025-11-30 | -$38.4 million | 2026-02-27 |
| Basic weighted-average shares | 2024-12-01 | 2025-11-30 | 8.07 million shares | 2026-02-27 |
| Diluted weighted-average shares | 2024-12-01 | 2025-11-30 | 8.07 million shares | 2026-02-27 |
| Basic earnings per share | 2024-12-01 | 2025-11-30 | -$0.30 per share | 2026-02-27 |
| Diluted earnings per share | 2024-12-01 | 2025-11-30 | -$0.30 per share | 2026-02-27 |
| Income tax expense or benefit | 2024-12-01 | 2025-11-30 | $92.2 thousand | 2026-02-27 |
| Net property, plant and equipment | - | 2025-11-30 | $21.0 million | 2026-02-27 |
| Share-based compensation expense | 2024-12-01 | 2025-11-30 | $417.1 thousand | 2026-02-27 |
| Operating income or loss | 2024-12-01 | 2025-11-30 | $482.4 thousand | 2026-02-27 |
| Current assets | - | 2025-11-30 | $11.8 million | 2026-02-27 |
| Interest expense | 2024-12-01 | 2025-11-30 | $2.07 million | 2026-02-27 |
| Current liabilities | - | 2025-11-30 | $19.8 million | 2026-02-27 |
| Current accounts payable | - | 2025-11-30 | $2.87 million | 2026-02-27 |
| Goodwill carrying amount | - | 2025-11-30 | $1.94 million | 2026-02-27 |
| Net finite-lived intangible assets | - | 2025-11-30 | $863.1 thousand | 2026-02-27 |
| Net current accounts receivable | - | 2025-11-30 | $6.85 million | 2026-02-27 |
| Common-stock repurchase payments | 2024-12-01 | 2025-11-30 | $169.5 thousand | 2026-02-27 |
| Net inventory | - | 2025-11-30 | $408.8 thousand | 2026-02-27 |
| Selling, general and administrative expense | 2024-12-01 | 2025-11-30 | $18.2 million | 2026-02-27 |
| Research and development expense | 2024-12-01 | 2025-11-30 | $376.3 thousand | 2026-02-27 |
| Common shares outstanding | - | 2025-11-30 | 8.06 million shares | 2026-02-27 |
| Operating lease right-of-use asset | - | 2025-11-30 | $819.6 thousand | 2026-02-27 |
| Operating lease liability | - | 2025-11-30 | $904.8 thousand | 2026-02-27 |
| Long-term debt | - | 2025-11-30 | $8.35 million | 2026-02-27 |
| Gross property, plant and equipment | - | 2025-11-30 | $27.6 million | 2026-02-27 |
| Accumulated depreciation on property, plant and equipment | - | 2025-11-30 | $6.56 million | 2026-02-27 |
| Net intangible assets excluding goodwill | - | 2025-11-30 | $863.1 thousand | 2026-02-27 |
| Other noncurrent assets | - | 2025-11-30 | $28.9 million | 2026-02-27 |
| Other noncurrent liabilities | - | 2025-11-30 | $60.5 million | 2026-02-27 |
| Accrued current liabilities | - | 2025-11-30 | $4.28 million | 2026-02-27 |
| Current contract liabilities | - | 2025-11-30 | $9.73 million | 2026-02-27 |
| Pre-tax income or loss from continuing operations | 2024-12-01 | 2025-11-30 | -$2.34 million | 2026-02-27 |
| Profit or loss including noncontrolling interests | 2024-12-01 | 2025-11-30 | -$2.43 million | 2026-02-27 |
| Depreciation expense | 2024-12-01 | 2025-11-30 | $927.0 thousand | 2026-02-27 |
| Depreciation, depletion and amortization | 2024-12-01 | 2025-11-30 | $985.2 thousand | 2026-02-27 |
| Amortization of intangible assets | 2024-12-01 | 2025-11-30 | $58.0 thousand | 2026-02-27 |
| Nonoperating interest expense | 2024-12-01 | 2025-11-30 | $2.07 million | 2026-02-27 |
| Other nonoperating income or expense | 2024-12-01 | 2025-11-30 | $53.0 thousand | 2026-02-27 |
| Nonoperating income or expense | 2024-12-01 | 2025-11-30 | -$2.82 million | 2026-02-27 |
| Current income tax expense or benefit | 2024-12-01 | 2025-11-30 | $2.91 million | 2026-02-27 |
| Deferred income tax expense or benefit | 2024-12-01 | 2025-11-30 | -$2.82 million | 2026-02-27 |
| Interest paid, net | 2024-12-01 | 2025-11-30 | $2.03 million | 2026-02-27 |
| Income taxes paid, net | 2024-12-01 | 2025-11-30 | $4.59 million | 2026-02-27 |
| Operating lease payments | 2024-12-01 | 2025-11-30 | $504.8 thousand | 2026-02-27 |
| Change in accounts receivable | 2024-12-01 | 2025-11-30 | $405.9 thousand | 2026-02-27 |
| Change in inventories | 2024-12-01 | 2025-11-30 | -$56.2 thousand | 2026-02-27 |
| Change in accounts payable | 2024-12-01 | 2025-11-30 | $1.00 million | 2026-02-27 |
Older measures: 5 not reported in the two years before 2026-09-20
| Measure | Period start | Period end | Value | Filed |
|---|---|---|---|---|
| Revenue | 2016-12-01 | 2017-11-30 | $25.4 million | 2018-02-28 |
| Additional paid-in capital | - | 2013-11-30 | $27.3 million | 2014-02-28 |
| Accumulated other comprehensive income or loss | - | 2018-11-30 | $341.0 thousand | 2020-02-28 |
| Prepaid expenses and other current assets | - | 2013-11-30 | $645.0 thousand | 2014-02-28 |
| Comprehensive income or loss | 2018-12-01 | 2019-11-30 | $2.29 million | 2020-02-28 |
Filings
- 10-Q filed 2026-07-15
- 10-Q filed 2026-04-14
- 10-K filed 2026-02-27
- 10-Q filed 2025-10-15
- 10-Q filed 2025-07-15
60 Cryo-Cell International filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.
Inspect the source
- Entity
- CRYO-CELL INTERNATIONAL, INC. / CIK 0000862692
- Captured
- SEC response SHA-256
db6274ac13e8b9460d5d6692afefc40788c565b8fd343e40b722f12a7b8f95ac
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000862692.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))